Market Cap 5.50B
Revenue (ttm) 4.79B
Net Income (ttm) -317.00M
EPS (ttm) N/A
PE Ratio 37.57
Forward PE 30.93
Profit Margin -6.62%
Debt to Equity Ratio 0.76
Volume 310,348
Avg Vol 510,770
Day's Range N/A - N/A
Shares Out 354.09M
Stochastic %K 65%
Beta 0.63
Analysts Sell
Price Target $15.14

Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeut...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 905-695-7700
Address:
520 Applewood Crescent, Vaughan, Canada
vcd103
vcd103 Oct. 26 at 1:08 AM
$BHC $BLCO RBC had this interesting comment on potential sale timing.. RBC Capital has reiterated its Market Perform rating and US$10 price target on Bausch Health Companies (BHC.NaE) ahead of its third-quarter results. Analyst Douglas Miehm estimates third quarter revenue of US$2.65 billion (vs. cons. US$2.62 billion). Key areas of focus include updates on the ongoing Xifaxan patent litigation and potential policy-related headwinds, Miehm notes. "Additionally, we will look for commentary on management's strategic vision for the BLCO asset. In our view, should a sale of the asset materialize, it would most likely occur in the 2026/2027 time frame."
1 · Reply
CindyH0o
CindyH0o Oct. 24 at 7:27 AM
$BHC jaw dropping. J. Paulson latest filing of BHC ownership. $BLCO
2 · Reply
ChubbRock999
ChubbRock999 Oct. 22 at 11:57 AM
$BHC if $COO and $BLCO were to merge, would BHC have to approve it?
1 · Reply
smartoptionstrader
smartoptionstrader Oct. 20 at 6:14 PM
ACTIVIST ALERT: Jana Partners took a stake in $COO demanding a breakup or merger with $BLCO. Stock popped 6%+ but could be just the start. Jana has a 30% annual return track record forcing value-unlocking deals. Bausch + Lomb's CEO already endorsed the merger publicly—rare and bullish. $COO trades at $75 after holding critical support at $61.77, with technical resistance at $112-$116. Historical activist campaigns generate 30-50% premiums. Options traders positioning in 3-6 month calls as implied volatility spikes. Risk-reward heavily favors bulls here. Cooper Companies (COO) Monthly Chart from Barchart - Shows the bearish trend reversal at critical support ($61.77 near October 2022 low of $61.05), recent recovery to $75+, and technical resistance levels at September 2024 high ($112.38) and September 2021 record peak ($115.90). The chart illustrates the significant upside potential from current levels to previous highs.
0 · Reply
topstockalerts
topstockalerts Oct. 20 at 12:41 PM
Cooper Cos. Stock Rises on Jana Partners' Activist Push Cooper Cos. saw its stock rise over 4% before market open on Monday after the Wall Street Journal reported that activist investor Jana Partners has built a stake in the company and plans to push for strategic alternatives, including potentially merging its contact lens unit with rival Bausch + Lomb. Jana believes the two business units of Cooper lack synergies and will advocate for changes to improve stock performance through better capital allocation and returns. The size of Jana's stake was not disclosed. The activist plan is already supported by Bausch + Lomb CEO Brent Saunders, who expressed interest in the potential merger in an interview. Cooper operates through two segments: CooperVision, a leading producer of soft contact lenses, and CooperSurgical, which provides women's health and fertility products and services. $COO $BLCO
0 · Reply
EarlyBirdEmail
EarlyBirdEmail Oct. 20 at 10:45 AM
$DOGE.X $COO $BLCO $PPRUY $LRLCY Some renewed buzz surrounding Elon Musk’s X platform and Dogecoin sent the price of the cryptocurrency up about 3% on Sunday. https://www.earlybird.email/p/dogecoin-new-elon-musk-buzz
0 · Reply
Tokenist
Tokenist Oct. 20 at 10:14 AM
$COO popping premarket — up 6% after activist fund Jana Partners took a stake in The Cooper Companies and started pushing for big changes. 💣 Jana wants a strategic review, calling for Cooper to split its businesses, the contact lens giant CooperVision and the women’s health unit CooperSurgical — saying the combo has dragged down shareholder returns. 👀 Rumors are swirling that $BLCO (Bausch + Lomb) CEO Brent Saunders is open to merging the contact lens divisions, potentially creating a major new player in the eye care market. 📈 After lagging hard this year (-21% YTD), investors are betting Jana’s involvement could unlock serious value. Analysts have a $79.45 PT, about 10% upside, but a merger or breakup could change that fast. 💬 $COO last traded at $76.50, and traders are watching closely — this could be the start of an activist-fueled comeback story.
1 · Reply
DonCorleone77
DonCorleone77 Oct. 20 at 2:13 AM
$COO $BLCO From The Wall Street Journal: "Activist Jana Takes Stake in Cooper, a Maker of Medical Devices" -- Bausch + Lomb is considered a potential partner for contact-lens unit, and CEO says he would be interested https://www.wsj.com/business/deals/activist-jana-takes-stake-in-cooper-a-maker-of-medical-devices-20ffbe9c?mod=hp_lead_pos6
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 20 at 1:25 AM
Activist Investor Turns Up Heat On Cooper, Urges Bausch + Lomb Merger To Boost Returns: Report $COO $BLCO https://stocktwits.com/news/equity/markets/activist-investor-turns-up-heat-on-cooper-urges-bausch-lomb-merger-to-boost-returns-report/ch6CWJvR3oK
0 · Reply
kbingo12
kbingo12 Oct. 20 at 12:40 AM
$BLCO Exclusive: Jana Partners has a stake in medical-devices maker Cooper and plans to urge a deal to combine its contact-lens unit with rival Bausch + Lomb.
0 · Reply
Latest News on BLCO
Bausch + Lomb Announces Board Changes

Aug 18, 2025, 5:01 PM EDT - 2 months ago

Bausch + Lomb Announces Board Changes


Bausch + Lomb to Participate in Upcoming Investor Conferences

Aug 14, 2025, 7:15 AM EDT - 2 months ago

Bausch + Lomb to Participate in Upcoming Investor Conferences


Bausch + Lomb Announces Second-Quarter 2025 Results

Jul 30, 2025, 6:57 AM EDT - 3 months ago

Bausch + Lomb Announces Second-Quarter 2025 Results


Bausch + Lomb Corporation (BLCO) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 11:02 AM EDT - 6 months ago

Bausch + Lomb Corporation (BLCO) Q1 2025 Earnings Call Transcript


Bausch + Lomb Announces First-Quarter 2025 Results

Apr 30, 2025, 6:57 AM EDT - 6 months ago

Bausch + Lomb Announces First-Quarter 2025 Results


Bausch + Lomb Corporation (BLCO) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 12:19 PM EST - 8 months ago

Bausch + Lomb Corporation (BLCO) Q4 2024 Earnings Call Transcript


Bausch & Lomb to shake up contact lenses with deal off the table

Feb 19, 2025, 9:16 AM EST - 8 months ago

Bausch & Lomb to shake up contact lenses with deal off the table


Bausch Health Provides Update on Strategic Alternatives

Feb 6, 2025, 7:05 AM EST - 9 months ago

Bausch Health Provides Update on Strategic Alternatives

BHC


vcd103
vcd103 Oct. 26 at 1:08 AM
$BHC $BLCO RBC had this interesting comment on potential sale timing.. RBC Capital has reiterated its Market Perform rating and US$10 price target on Bausch Health Companies (BHC.NaE) ahead of its third-quarter results. Analyst Douglas Miehm estimates third quarter revenue of US$2.65 billion (vs. cons. US$2.62 billion). Key areas of focus include updates on the ongoing Xifaxan patent litigation and potential policy-related headwinds, Miehm notes. "Additionally, we will look for commentary on management's strategic vision for the BLCO asset. In our view, should a sale of the asset materialize, it would most likely occur in the 2026/2027 time frame."
1 · Reply
CindyH0o
CindyH0o Oct. 24 at 7:27 AM
$BHC jaw dropping. J. Paulson latest filing of BHC ownership. $BLCO
2 · Reply
ChubbRock999
ChubbRock999 Oct. 22 at 11:57 AM
$BHC if $COO and $BLCO were to merge, would BHC have to approve it?
1 · Reply
smartoptionstrader
smartoptionstrader Oct. 20 at 6:14 PM
ACTIVIST ALERT: Jana Partners took a stake in $COO demanding a breakup or merger with $BLCO. Stock popped 6%+ but could be just the start. Jana has a 30% annual return track record forcing value-unlocking deals. Bausch + Lomb's CEO already endorsed the merger publicly—rare and bullish. $COO trades at $75 after holding critical support at $61.77, with technical resistance at $112-$116. Historical activist campaigns generate 30-50% premiums. Options traders positioning in 3-6 month calls as implied volatility spikes. Risk-reward heavily favors bulls here. Cooper Companies (COO) Monthly Chart from Barchart - Shows the bearish trend reversal at critical support ($61.77 near October 2022 low of $61.05), recent recovery to $75+, and technical resistance levels at September 2024 high ($112.38) and September 2021 record peak ($115.90). The chart illustrates the significant upside potential from current levels to previous highs.
0 · Reply
topstockalerts
topstockalerts Oct. 20 at 12:41 PM
Cooper Cos. Stock Rises on Jana Partners' Activist Push Cooper Cos. saw its stock rise over 4% before market open on Monday after the Wall Street Journal reported that activist investor Jana Partners has built a stake in the company and plans to push for strategic alternatives, including potentially merging its contact lens unit with rival Bausch + Lomb. Jana believes the two business units of Cooper lack synergies and will advocate for changes to improve stock performance through better capital allocation and returns. The size of Jana's stake was not disclosed. The activist plan is already supported by Bausch + Lomb CEO Brent Saunders, who expressed interest in the potential merger in an interview. Cooper operates through two segments: CooperVision, a leading producer of soft contact lenses, and CooperSurgical, which provides women's health and fertility products and services. $COO $BLCO
0 · Reply
EarlyBirdEmail
EarlyBirdEmail Oct. 20 at 10:45 AM
$DOGE.X $COO $BLCO $PPRUY $LRLCY Some renewed buzz surrounding Elon Musk’s X platform and Dogecoin sent the price of the cryptocurrency up about 3% on Sunday. https://www.earlybird.email/p/dogecoin-new-elon-musk-buzz
0 · Reply
Tokenist
Tokenist Oct. 20 at 10:14 AM
$COO popping premarket — up 6% after activist fund Jana Partners took a stake in The Cooper Companies and started pushing for big changes. 💣 Jana wants a strategic review, calling for Cooper to split its businesses, the contact lens giant CooperVision and the women’s health unit CooperSurgical — saying the combo has dragged down shareholder returns. 👀 Rumors are swirling that $BLCO (Bausch + Lomb) CEO Brent Saunders is open to merging the contact lens divisions, potentially creating a major new player in the eye care market. 📈 After lagging hard this year (-21% YTD), investors are betting Jana’s involvement could unlock serious value. Analysts have a $79.45 PT, about 10% upside, but a merger or breakup could change that fast. 💬 $COO last traded at $76.50, and traders are watching closely — this could be the start of an activist-fueled comeback story.
1 · Reply
DonCorleone77
DonCorleone77 Oct. 20 at 2:13 AM
$COO $BLCO From The Wall Street Journal: "Activist Jana Takes Stake in Cooper, a Maker of Medical Devices" -- Bausch + Lomb is considered a potential partner for contact-lens unit, and CEO says he would be interested https://www.wsj.com/business/deals/activist-jana-takes-stake-in-cooper-a-maker-of-medical-devices-20ffbe9c?mod=hp_lead_pos6
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 20 at 1:25 AM
Activist Investor Turns Up Heat On Cooper, Urges Bausch + Lomb Merger To Boost Returns: Report $COO $BLCO https://stocktwits.com/news/equity/markets/activist-investor-turns-up-heat-on-cooper-urges-bausch-lomb-merger-to-boost-returns-report/ch6CWJvR3oK
0 · Reply
kbingo12
kbingo12 Oct. 20 at 12:40 AM
$BLCO Exclusive: Jana Partners has a stake in medical-devices maker Cooper and plans to urge a deal to combine its contact-lens unit with rival Bausch + Lomb.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 9 at 5:34 PM
Results of list 9/26/25 $BLCO $BLD $BLDR $BLFS The list has 1 more day to go tomorrow. After an audit of 400 calls 291 hit the targets that's an 72.9% accuracy for the first 400 calls there is way more calls in the sheet any one that will want access to the Google sheet can sent me a private message and you can audit the rest of the Google sheet your self. 🔥 Cycle Trading Signal plugged into AI 🔥 list. @Stocktwits
0 · Reply
JarvisFlow
JarvisFlow Oct. 7 at 4:32 PM
Evercore ISI Group has updated their rating for Bausch & Lomb ( $BLCO ) to Outperform with a price target of 17.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Oct. 6 at 12:02 AM
$BLCO Massive volume increase with 811,100 shares traded on Oct 1 compared to the 699,116 average volume. Price moved from $14.67 to $15.20. Smart move to wait for a lower H% before considering entry.
0 · Reply
SlowDriver
SlowDriver Oct. 1 at 6:53 PM
$BHC $BLCO are we up today because the government shut down? Does this stop, or delay, the Inflation Reduction Act from moving ahead?
0 · Reply
JarvisFlow
JarvisFlow Oct. 1 at 5:50 PM
Goldman Sachs has adjusted their stance on Bausch & Lomb ( $BLCO ), setting the rating to Neutral with a target price of 16.
0 · Reply
BW69
BW69 Sep. 3 at 2:24 PM
$BHC $BLCO 88% not 80%!
0 · Reply
vcd103
vcd103 Aug. 30 at 11:48 AM
$BHC in the beginning of the year i felt that we might see some progress on the spinoff that has become stalled-off through deregulation and perhaps an uptick in M&A. However, the replacement of major health care agencies wth kooks, bls firngs, indiscriminate tariffs (this company is Canadian), etc make such scenario unlikely. Nor do i see anybway how $BLCO gets back to its IPO price anytime soon. I will still hold on my shares .. perhaps the freaking stalled-off can be unwound and these companies are put back together..
1 · Reply
omar_progressivetrading
omar_progressivetrading Aug. 3 at 9:11 PM
$BLCO – Excited to initiate a long-term position. Current levels offer a 50% discount from all-time highs, and the fundamentals + structure look aligned. Excited to document what human behavior reveals on the charts over time. Patience. Discipline. Execution. To The Moon & Beyond! 🫡 🌖
0 · Reply
JarvisFlow
JarvisFlow Aug. 1 at 2:11 PM
Morgan Stanley has updated their rating for Bausch & Lomb ( $BLCO ) to Equal-Weight with a price target of 13.
0 · Reply
ebu
ebu Aug. 1 at 2:21 AM
$BHC I can't think of any company where a stock split happened May 6th 2022. And it's shareholders are still waiting for 80% of $BLCO shares. Its unbelievable that 3 years and 3 months have past since then.
5 · Reply
JarvisFlow
JarvisFlow Jul. 31 at 3:40 PM
Wells Fargo has updated their rating for Bausch & Lomb ( $BLCO ) to Equal-Weight with a price target of 15.
0 · Reply
kbingo12
kbingo12 Jul. 30 at 2:19 PM
its amazing how poor performance continues at $BLCO and $BHC and management never changes.
0 · Reply